These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33032648)

  • 21. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gilteritinib or Chemotherapy for Relapsed or Refractory
    Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
    N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
    Hogan FL; Williams V; Knapper S
    Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
    Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan.
    Kiguchi T; Sakurai M; Tanaka Y; Kuramoto K; Kado Y; Sawada S; Mitomi T
    Curr Med Res Opin; 2023 Nov; 39(11):1513-1522. PubMed ID: 37881860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
    Mohebbi A; Shahriyary F; Farrokhi V; Bandar B; Saki N
    Leuk Res; 2024 Jun; 141():107505. PubMed ID: 38692232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation].
    Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063
    [No Abstract]   [Full Text] [Related]  

  • 34. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.
    Bruzzese A; Vigna E; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Stanzione G; Zimbo A; Lugli E; Neri A; Morabito F; Gentile M
    Expert Rev Hematol; 2024 Jun; 17(6):241-253. PubMed ID: 38748404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
    McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
    Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in
    Cortes JE; Tallman MS; Schiller GJ; Trone D; Gammon G; Goldberg SL; Perl AE; Marie JP; Martinelli G; Kantarjian HM; Levis MJ
    Blood; 2018 Aug; 132(6):598-607. PubMed ID: 29875101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quizartinib for the treatment of acute myeloid leukemia.
    Garcia-Horton A; Yee KW
    Expert Opin Pharmacother; 2020 Dec; 21(17):2077-2090. PubMed ID: 32772726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
    Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
    J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.